165 related articles for article (PubMed ID: 30443013)
1. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
2. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
[TBL] [Abstract][Full Text] [Related]
3. Microtubule-organizing center-mediated structural atypia in low- and high-grade urothelial carcinoma.
Murata SI; Kuroda M; Kawamura N; Warigaya K; Musangile FY; Matsuzaki I; Kojima F
Virchows Arch; 2021 Feb; 478(2):327-334. PubMed ID: 32710188
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder.
Li C; Xue H; Lei Y; Zhu J; Yang B; Gai X
Pathol Res Pract; 2014 Dec; 210(12):799-803. PubMed ID: 25445116
[TBL] [Abstract][Full Text] [Related]
5. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
6. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of cytohistological urine analysis and cytokeratin 20 in malignant and atypical urothelial cells.
Negri S; Biavati P; Bondi A
Pathologica; 2016 Sep; 108(3):130-135. PubMed ID: 28195264
[TBL] [Abstract][Full Text] [Related]
8. Keratin 17 is a negative prognostic biomarker in high-grade endometrial carcinomas.
Bai JDK; Babu S; Roa-Peña L; Hou W; Akalin A; Escobar-Hoyos LF; Shroyer KR
Hum Pathol; 2019 Dec; 94():40-50. PubMed ID: 31655172
[TBL] [Abstract][Full Text] [Related]
9. Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
Edgecombe A; Nguyen BN; Djordjevic B; Belanger EC; Mai KT
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):264-71. PubMed ID: 22498670
[TBL] [Abstract][Full Text] [Related]
10. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder.
Lee H; Jun SY; Lee YS; Lee HJ; Lee WS; Park CS
Virchows Arch; 2014 Feb; 464(2):213-20. PubMed ID: 24306957
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
[TBL] [Abstract][Full Text] [Related]
12. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
14. Implications of androgen receptor and FUS expression on tumor progression in urothelial carcinoma.
Abd Raboh NM; Hakim SA; Abd El Atti RM
Histol Histopathol; 2021 Mar; 36(3):325-337. PubMed ID: 33354760
[TBL] [Abstract][Full Text] [Related]
15. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor expression in papillary urothelial carcinoma of the bladder and ovarian transitional cell carcinoma.
Croft PR; Lathrop SL; Feddersen RM; Joste NE
Arch Pathol Lab Med; 2005 Feb; 129(2):194-9. PubMed ID: 15679420
[TBL] [Abstract][Full Text] [Related]
18. An institutional experience evaluating hTERT immunostaining in 100 consecutive ThinPrep urine specimens.
Xing J; Han M; Monaco SE; Dhir R; Roy S; Pantanowitz L
J Am Soc Cytopathol; 2021; 10(1):88-93. PubMed ID: 32354607
[TBL] [Abstract][Full Text] [Related]
19. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
20. The effects of the current World Health Organization/International Society of Urologic Pathologists bladder neoplasm classification system on urine cytology results.
Curry JL; Wojcik EM
Cancer; 2002 Jun; 96(3):140-5. PubMed ID: 12115301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
